

31 August 2026

Tender results – 2024/25 & 2025/26 Invitation to Tender

Pharmac has resolved to award or not award tenders for Principal Supply Status for some products included in the 2024/25 Invitation to Tender dates 31 October 2024 and in the 2025/26 Invitation to Tender dated 3 November 2025.

Some of the Pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with Pharmac. Suppliers of Pharmaceuticals that are subject to such contracts should continue to supply their Pharmaceutical under those contracts. Pharmac will continue to subsidise those Pharmaceuticals accordingly until such time as those Pharmaceuticals are delisted.


Notification of Product Changes (NOPC) forms

Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to Pharmac, the Pharmacy Guild and the NZULM by:

- **For new listings**, by 4pm on the 12th of September 2026 or the 5th of the month prior to listing, whichever is earlier
- **For price changes**, by 4pm on the 12th of the month prior to the date of subsidy change

Pharmac cannot list a product (and Pharmacies cannot claim) without this information. More information about this process, and a copy of the NOPC form can be found on our website – <https://pharmac.govt.nz/medicine-funding-and-supply/make-an-application/pharmconnect-make-a-medicine-funding-application/process-for-notification-of-product-changes/>

Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand (<https://www.pgnz.org.nz/our-trading-arm-psl>) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines (<http://www.nzulm.org.nz/sponsors>). Pharmacodes and CTPP codes must be provided to Pharmac by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). Pharmac cannot list a product (and Pharmacies cannot claim) without the correct Pharmacode.




2025/26 Invitation to Tender – Principal Supply Status applies until 30 June 2029

Community Pharmaceutical tenders – Section B of the Pharmaceutical Schedule


1. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed (no brand change).*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date
Aripiprazole	Tab 5 mg; 30 tablet blister pack	\$10.50	\$6.90	Aripiprazole Sandoz (Sandoz)	1 October 2026	1 March 2027
Aripiprazole	Tab 10 mg; 30 tablet blister pack	\$10.50	\$6.90	Aripiprazole Sandoz (Sandoz)	1 October 2026	1 March 2027
Aripiprazole	Tab 15 mg; 30 tablet blister pack	\$10.50	\$7.41	Aripiprazole Sandoz (Sandoz)	1 October 2026	1 March 2027
Aripiprazole	Tab 20 mg; 30 tablet blister pack	\$10.50	\$7.41	Aripiprazole Sandoz (Sandoz)	1 October 2026	1 March 2027
Aripiprazole	Tab 30 mg; 30 tablet blister pack	\$10.50	\$7.41	Aripiprazole Sandoz (Sandoz)	1 October 2026	1 March 2027



2. *Tenders awarded to pharmaceuticals where at least one other brand is listed (the funded brand will change).*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	Date of subsidy change	Principal Supply date	Brand (Supplier) affected by delisting
Amorolfine	Nail soln 5%; 5 ml glass bottle	\$21.87	\$16.62	Aporyl (Arrotex)	1 April 2027	1 September 2027	MycoNail (AFT)
Cetirizine hydrochloride	Tab 10 mg; 90 tablet blister pack	\$1.71 (per 100)	\$1.00	Cetirizine (Ipca) (Miro)	1 March 2027	1 August 2027	Zista (Teva)
Dapsone	Tab 100 mg; 100 tablet blister pack	\$329.50	\$212.98	Dapsomed (Medsurge)	1 October 2026	1 March 2027	Dapsone (Link)
Fluconazole	Cap 50 mg; 28 capsule blister pack	\$4.10	\$8.00	Ipca-Fluconazole (Miro)	1 May 2027	1 October 2027	Mylan (Arrotex)
Fluconazole	Cap 150 mg; 1 capsule blister pack	\$0.45	\$2.50	Ipca-Fluconazole (Miro)	1 May 2027	1 October 2027	Mylan (Arrotex) Flucazole (Arrotex)
Fluconazole	Cap 200 mg; 28 capsule blister pack	\$8.90	\$20.00	Ipca-Fluconazole (Miro)	1 May 2027	1 October 2027	Mylan (Arrotex)
Ibuprofen	Tab 200 mg; 1,000 tablet blister pack	\$21.40	\$15.90	Ethics Ibuprofen (Multichem)	1 May 2027	1 December 2027	Relieve (Viatris)




3. *Tenders awarded to pharmaceuticals not currently listed on the Pharmaceutical Schedule (new investments).*

Chemical name	Presentation; Pack size and type	Pack price	Principal Supply brand (Supplier)	Date of Listing	Principal Supply date
Dapsone ¹	Tab 50 mg; 100 tablet blister pack	\$188.28	Dapsomed (Medsurge)	1 October 2026	1 March 2027
¹ Dapsone tab 25 mg to be delisted from the Pharmaceutical Schedule on 1 March 2027. Dapsone tab 25 mg is currently supplied by Link Pharmaceuticals under the brand names Dapsone and Dapsone (Rising). Please see below for further detail.					

Hospital Pharmaceutical tenders – Section H of the Pharmaceutical Schedule.

4. *Tenders awarded to currently listed pharmaceuticals where no other brand is listed (no brand change)*


Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Date of subsidy change	Principal Supply date
Aripiprazole	Tab 5 mg; 30 tablet blister pack	\$10.50	\$6.90	Aripiprazole Sandoz (Sandoz)	5%	1 October 2026	1 March 2027
Aripiprazole	Tab 10 mg; 30 tablet blister pack	\$10.50	\$6.90	Aripiprazole Sandoz (Sandoz)	5%	1 October 2026	1 March 2027
Aripiprazole	Tab 15 mg; 30 tablet blister pack	\$10.50	\$7.41	Aripiprazole Sandoz (Sandoz)	5%	1 October 2026	1 March 2027
Aripiprazole	Tab 20 mg; 30 tablet blister pack	\$10.50	\$7.41	Aripiprazole Sandoz (Sandoz)	5%	1 October 2026	1 March 2027



Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Date of subsidy change	Principal Supply date
Aripiprazole	Tab 30 mg; 30 tablet blister pack	\$10.50	\$7.41	Aripiprazole Sandoz (Sandoz)	5%	1 October 2026	1 March 2027

5. *Tenders awarded to pharmaceuticals where at least one other brand is listed (the funded brand will change).*

Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Date of subsidy change	Principal Supply date	Brand (Supplier) affected by delisting
Amorolfine	Nail soln 5%; 5 ml glass bottle	\$21.87	\$16.62	Aporyl (Arrotex)	5%	1 April 2027	1 September 2027	MycoNail (AFT)
Ceftazidime	Inj 1 g vial; 5 vial pack	\$25.80 (per 10)	\$11.17	Ceftazidime Viartis (Viartis)	5%	1 June 2027	1 November 2027	Ceftazidime Kabi (Fresenius Kabi)
Cetirizine hydrochloride	Tab 10 mg; 90 tablet blister pack	\$1.71 (per 100)	\$1.00	Cetirizine (Ipca) (Miro)	5%	1 March 2027	1 August 2027	Zista (Teva)
Dapsone	Tab 100 mg; 100 tablet blister pack	\$329.50	\$212.98	Dapsomed (Medsurge)	5%	1 October 2026	1 March 2027	Dapsone (Link)
Fluconazole	Cap 50 mg; 28 capsule blister pack	\$4.10	\$8.00	Ipca-Fluconazole (Miro)	5%	1 May 2027	1 October 2027	Mylan (Arrotex)
Fluconazole	Cap 150 mg; 1 capsule blister pack	\$0.45	\$2.50	Ipca-Fluconazole (Miro)	5%	1 May 2027	1 October 2027	Mylan (Arrotex) Fluconazole (Arrotex)
Fluconazole	Cap 200 mg; 28 capsule blister pack	\$8.90	\$20.00	Ipca-Fluconazole (Miro)	5%	1 May 2027	1 October 2027	Mylan (Arrotex)



Chemical name	Presentation; Pack size and type	Current pack price	New pack price	Principal Supply brand (Supplier)	DV Limit	Date of subsidy change	Principal Supply date	Brand (Supplier) affected by delisting
Ibuprofen	Tab 200 mg; 1,000 tablet blister pack	\$21.40	\$15.90	Ethics Ibuprofen (Multichem)	5%	1 May 2027	1 December 2027	Relieve (Viatris)

6. *Tenders awarded to pharmaceuticals not currently listed on the Pharmaceutical Schedule (new investments).*

Chemical name	Presentation; Pack size and type	Pack price	Principal Supply brand (Supplier)	DV Limit	Date of listing	Principal Supply date
Dapsone ¹	Tab 50 mg; 100 tablet blister pack	\$188.28	Dapsomed (Medsurge)	5%	1 October 2026	1 March 2027


¹Dapsone tab 25 mg to be delisted from the Pharmaceutical Schedule on 1 March 2027. Dapsone tab 25 mg is currently supplied by Link Pharmaceuticals under the brand names Dapsone and Dapsone (Rising). Please see below for further detail.

Dapsone

What's changing?

This decision will result in a change of the funded brands of dapsone tablets, which are currently supplied by Link Pharmaceuticals under the brand names Dapsone and Dapsone (Rising). The new funded brand of dapsone tablets will be supplied by Medsurge, under the brand name Dapsomed. This decision will also result in the 25 mg tablet being removed from the Pharmaceutical Schedule and replaced with a 50 mg tablet. The new 50 mg tablet can be halved to achieve a 25 mg dose.

Following feedback, we have also made the decision to amend the prescribing restriction for dapsone to allow any relevant specialist to prescribe.



Reason for Change

The change from a 25 mg tablet to a 50 mg tablet is being made because the currently funded dapsone tablets are being discontinued by the manufacturer. We expect stock of the currently funded 25 mg and 50 mg tablets will run out by the end of 2026. Pharmac has not been able to secure alternative supply of Medsafe approved 25 mg tablets.

We have been working with suppliers to manage this discontinuation. Through this decision, Pharmac has been able to secure supply of both 50 mg and 100 mg dapsone tablets, from Medsurge.

Tender declines – Products where no tender is to be awarded for Principal Supply Status

Pharmac has resolved not to award tenders for Principal Supply Status for the following product listed in the 2024/25 Invitation to Tender, dated 31 October 2024.

Chemical Name	Line Item
Iron (as ferric carboxymaltose)	Inj 50 mg per ml, 10 ml vial